Artificial IntelligenceData from Brainomix’s Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline
Brainomix, the AI-powered medtech company, announces the publication of a new study in the prestigious peer-reviewed journal American Journal of Respiratory and Critical Care Medicine (AJRCCM)1, resulting from a research collaboration AstraZeneca, the UK’s leading Biopharmaceutical company. The results showed that Brainomix e-Lung, an AI-enabled automated CT processing software, stratifies patients at risk of IPF progression, outperforming standard measures, and demonstrating e-Lung’s potential role in improving efficiency of of future clinical trials. The study was an...